|
Lauren classification
|
P# value
|
HER2 status
|
P* value
|
---|
Diffuse(%)
|
Intestinal(%)
|
Mixed(%)
|
Negative(%)
|
Positive(%)
|
---|
Sex
| | | |
<0.0
| | | |
Male
|
242 (43.7)
|
216 (39.0)
|
96 (17.3)
|
01
|
486 (87.7)
|
68 (12.3)
|
0.176
|
Female
|
185 (64.7)
|
68 (23.9)
|
31 (10.9)
|
258 (90.8)
|
26 (9.2)
|
Age
| | | |
<0.001
| | |
<0.001
|
≤59
|
269 (62.7)
|
104 (24.2)
|
56 (13.1)
|
398 (92.8)
|
31 (7.2)
|
>59
|
158 (38.6)
|
180 (44.0)
|
71 (17.4)
|
346 (84.6)
|
63 (15.4)
|
Stage
| | | |
<0.001
| | |
0.406
|
I
|
68 (47.9)
|
60 (42.3)
|
14 (9.8)
|
131(92.3)
|
11 (7.7)
|
II
|
96 (41.7)
|
102 (44.3)
|
32 (13.9)
|
203 (88.3)
|
27 (11.7)
|
III
|
215 (56.9)
|
95 (25.1)
|
68 (18.0)
|
335 (88.6)
|
43 (11.4)
|
IV
|
48 (54.5)
|
27 (30.7)
|
13 (14.8)
|
75 (85.2)
|
13 (14.8)
|
Degree of differentiation
| | | |
<0.001
| | |
<0.001
|
Well + Moderate
|
0 (0)
|
262 (76.2)
|
82 (23.8)
|
270 (78.5)
|
74 (21.5)
|
Poor + signet ring cell
|
427 (86.4)
|
22 (4.5)
|
45 (9.1)
|
474 (96.0)
|
20 (4.0)
|
Location
| | | |
<0.001
| | |
<0.001
|
Proximal
|
110 (35.9)
|
146 (47.7)
|
50 (16.3)
|
251 (82.0)
|
55 (18.0)
|
Distal
|
276 (59.1)
|
128 (27.4)
|
63 (13.5)
|
436 (93.4)
|
31 (6.6)
|
Total stomach
|
41 (63.1)
|
10 (15.4)
|
14 (21.5)
|
57 (87.7)
|
8 (12.3)
|
Adjuvant chemotherapy
| | | | | | | |
Yes
|
302 (51.4)
|
192 (32.7)
|
94 (15.9)
| |
531 (90.3)
|
57 (9.7)
| |
No
|
77 (47.5)
|
65 (40.1)
|
20 (12.4)
|
0.170
|
138 (85.2)
|
24 (14.8)
|
0.063
|
- HER2: human epidermal growth factor receptor 2.
- #P values of Lauren classification in different clinical features. *P values of HER 2 status in different clinical features.